iSTEP-G
Weight Loss / Metabolic Disease
Key Facts
About Akyso Therapeutics
Akyso Therapeutics is a clinical-stage biotech advancing the iSTEP platform, a tunable, bioabsorbable polymeric implant for ultra-long-acting drug delivery. Its lead program, iSTEP-N (naltrexone), has completed a Phase 1a trial, with a Phase 1b PK study slated for Q1 2026, targeting the significant compliance challenges in opioid use disorder treatment. The pipeline also includes a buprenorphine implant for OUD and exploratory work on a GLP-1 agonist implant for weight loss, positioning the company at the intersection of advanced drug delivery and high-need therapeutic areas. As a private, pre-revenue company, Akyso is seeking to translate its versatile technology into novel treatments that improve patient adherence and outcomes.
View full company profile